Literature DB >> 1893349

Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.

J A Ajani1, D M Ota, J M Jessup, F C Ames, C McBride, A Boddie, B Levin, D E Jackson, M Roh, D Hohn.   

Abstract

Patients with locoregional gastric carcinoma often die because of the low rates of curative resection and frequent appearance of distant metastases (mainly peritoneal and hepatic). To evaluate the feasibility of preoperative and postoperative chemotherapy, 25 consecutive previously untreated patients with potentially resectable locoregional gastric carcinoma received two preoperative and three postoperative courses of etoposide, 5-fluorouracil, and cisplatin (EFP). Ninety-eight courses (median, five courses; range, two to five courses) were administered. Six patients had major responses to EFP. Eighteen patients (72%) had curative resections, and three specimens (12%) contained only microscopic carcinoma. At a median follow-up of 25 months, the median survival of 25 patients was 15 months (range, 4 to 32+ months). Peritoneal carcinomatosis was the most common indication of failure. One patient died of postoperative complications, but there were no deaths due to chemotherapy. EFP-induced toxic reactions were moderate. Preoperative and postoperative chemotherapy for locoregional gastric carcinoma is feasible, and additional studies to develop regimens that could result in 5% to 10% complete pathologic responses may be warranted.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893349     DOI: 10.1002/1097-0142(19911001)68:7<1501::aid-cncr2820680706>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Gastric Cancer.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

2.  Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases.

Authors:  Emel Canbay; Yutaka Yonemura; Bjorn Brucher; Seung Hyuk Baik; Paul H Sugarbaker
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

3.  Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.

Authors:  Ulrike Heger; Franz Bader; Florian Lordick; Maria Burian; Rupert Langer; Martin Dobritz; Susanne Blank; Thomas Bruckner; Karen Becker; Ken Herrmann; Jörg-Rüdiger Siewert; Katja Ott
Journal:  Gastric Cancer       Date:  2013-09-01       Impact factor: 7.370

4.  Treatment of resectable gastric cancer.

Authors:  Johan L Dikken; Cornelis J H van de Velde; Daniel G Coit; Manish A Shah; Marcel Verheij; Annemieke Cats
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

Review 5.  Treatment options for surgically resectable gastric cancer.

Authors:  Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2010-06

6.  Perspectives of surgery and multimodality treatment in gastric carcinoma.

Authors:  H J Meyer; J Jähne; H Wilke
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 7.  Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy.

Authors:  J A Ajani; P F Mansfield; D M Ota
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

8.  Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication.

Authors:  Yanlei Ma; Huanlong Qin; Qi Zheng; Yu Wang; Zhiguo Wang; Zhe Yang
Journal:  Med Oncol       Date:  2009-11-03       Impact factor: 3.064

9.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

10.  Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.

Authors:  Deepa Magge; Mazen Zenati; Arun Mavanur; Joshua Winer; Lekshmi Ramalingam; Heather Jones; Amer Zureikat; Matthew Holtzman; Kenneth Lee; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-11-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.